Want to see IN:UNICHEMLAB full AI Analyst Report?
Top Page
Unichem Laboratories Limited
(UNICHEMLAB)
Select Model
Select Model
Rating:56Neutral
Price Target:
₹486.00
▲(9.69% Upside)
Action:Reiterated
Date:10/10/26
The score is held back primarily by weak cash-flow quality (negative operating cash flow and consistently negative free cash flow) and historically volatile profitability, despite a strong, conservative balance sheet and improved recent net profitability. Technicals are neutral with a short-term pullback, while valuation (P/E ~12.27) provides some support.
Positive Factors
Conservative Balance Sheet
Low leverage and a growing equity base provide financial resilience and preserve flexibility to support operations or future investment. This conservative capital structure reduces balance-sheet strain and gives Unichem greater capacity to manage industry volatility over the next several quarters.
Negative Factors
Weak Cash Conversion
Persistent negative operating and free cash flow means reported earnings are not translating reliably into cash resources. This can constrain internally funded growth, increase reliance on financial flexibility, and raise execution risk if investment needs remain high or operating conditions become less favorable.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Low leverage and a growing equity base provide financial resilience and preserve flexibility to support operations or future investment. This conservative capital structure reduces balance-sheet strain and gives Unichem greater capacity to manage industry volatility over the next several quarters.
Read all positive factors
Unichem Laboratories Limited (UNICHEMLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹34.04B
Dividend Yield1.34%
Average Volume (3M)11.51K
Price to Earnings (P/E)11.2
Beta (1Y)1.34
Revenue Growth9.43%
EPS Growth132.94%
CountryIN
Employees2,815
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)43.29
Shares Outstanding70,405,754
10 Day Avg. Volume3,020
30 Day Avg. Volume11,513
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.76
Price to Sales (P/S)0.94
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Unichem Laboratories Limited Business Overview & Revenue Model
Company Description
Unichem Laboratories Limited is an international pharmaceutical company engaged in the development, manufacturing, and commercialization of a wide array of medicinal products. The firm's portfolio features finished pharmaceutical formulations desi...
How the Company Makes Money
Unichem Laboratories makes money primarily by selling pharmaceutical products across a mix of business lines and geographies. Key revenue streams typically include: (1) Domestic formulations: revenue from marketing and distributing branded formula...
Unichem Laboratories Limited Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
74
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.08B | 22.02B | 21.11B | 16.57B | 13.25B | 12.56B |
| Gross Profit | 7.25B | 6.60B | 12.47B | 3.17B | 7.92B | 8.07B |
| EBITDA | 4.90B | 4.49B | 2.65B | 742.36M | -456.07M | 803.28M |
| Net Income | 3.05B | 2.53B | 1.38B | -704.74M | -2.02B | 330.62M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 37.37B | 35.69B | 31.69B | 31.93B | 33.19B |
| Cash, Cash Equivalents and Short-Term Investments | 2.89B | 2.99B | 895.80M | 1.52B | 1.89B | 3.73B |
| Total Debt | 0.00 | 5.00B | 4.60B | 2.48B | 3.14B | 3.49B |
| Total Liabilities | -27.17B | 10.20B | 11.19B | 8.07B | 7.58B | 7.00B |
| Stockholders Equity | 27.17B | 27.17B | 24.51B | 23.62B | 24.35B | 26.18B |
Cash Flow | ||||||
| Free Cash Flow | 408.30M | -1.39B | -1.44B | -58.53M | -1.29B | -3.87B |
| Operating Cash Flow | 994.40M | -156.90M | -70.20M | 166.94M | -850.91M | -2.60B |
| Investing Cash Flow | -375.90M | 1.86B | -2.41B | 504.04M | 2.03B | 1.00B |
| Financing Cash Flow | 259.10M | 267.90M | 1.84B | -1.06B | -813.00M | 1.91B |
Unichem Laboratories Limited Technical Analysis
Negative
443.05
Price Trends
529.67
Negative
519.85
Negative
440.06
Positive
Market Momentum
-14.29
Positive
39.18
Neutral
50.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:UNICHEMLAB, the sentiment is Negative. The current price of 443.05 is below the 20-day moving average (MA) of 511.10, below the 50-day MA of 529.67, and above the 200-day MA of 440.06, indicating a neutral trend. The MACD of -14.29 indicates Positive momentum. The RSI at 39.18 is Neutral, neither overbought nor oversold. The STOCH value of 50.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:UNICHEMLAB.
Unichem Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₹18.10B | 27.61 | ― | 0.72% | 18.53% | 1.89% | |
61 Neutral | ₹62.30B | 33.05 | ― | 0.18% | 30.20% | 91.17% | |
58 Neutral | ₹41.34B | 56.50 | ― | 0.02% | 16.70% | 18.73% | |
56 Neutral | ₹34.04B | 11.17 | ― | 1.34% | 9.43% | 132.94% | |
56 Neutral | ₹26.01B | -77.22 | ― | 0.28% | -5.37% | -153.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | ₹19.23B | 61.26 | ― | 0.10% | 10.75% | ― |
* General Sector Average
IN:UNICHEMLAB
Unichem Laboratories Limited
483.45
9.00
1.90%
IN:GUFICBIO
Gufic Biosciences Limited
412.20
84.68
25.85%
IN:HIKAL
Hikal Limited
210.95
-32.96
-13.51%
IN:INDOCO
Indoco Remedies Limited
208.35
-64.66
-23.68%
IN:MOREPENLAB
Morepen Laboratories Limited
113.70
65.56
136.19%
IN:WINDLAS
Windlas Biotech Ltd.
877.25
-76.09
-7.98%
Unichem Laboratories Limited Corporate Events
Exchange Seeks Clarification as Unichem Labs Shares See Volume Surge
Aug 25, 2026
A significant spike in trading volume has been recorded in the shares of Unichem Laboratories Limited, prompting closer attention from the stock exchange. The move signals heightened investor activity and possibly shifting sentiment toward the pha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.